CKF Tide Tables

GHRP-2

Quick Facts

PropertyValue
CategoryGrowth Hormone Secretagogue
Risk LevelModerate/High
AdministrationSubcutaneous Injection
Typical Frequency1–3 Times Daily
Estimated Half-LifeShort Plasma Half-Life
Primary Research InterestGrowth Hormone Release / Recovery / Appetite Signaling
Important Disclaimer

This material is provided strictly for educational and informational purposes related to peptide research and growth hormone signaling compounds. GHRP-2 is a biologically active growth hormone secretagogue capable of significantly altering growth hormone, cortisol, prolactin, and metabolic signaling pathways. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.

1. Reconstitution Guide

  • Vial Size: 10 mg
  • Dilutant Type: BAC Water
  • Amount of Dilutant Added: 3 mL
  • Final Concentration: 3.33 mg/mL

At this concentration:
• 100 mcg = 0.030 mL (3.0 units)
• 300 mcg = 0.090 mL (9.0 units)

2. Route of Administration

GHRP-2 is most commonly administered as a subcutaneous injectable growth hormone secretagogue.

  • Primary Route: SubQ Injection
  • Preferred Timing: Commonly administered in fasted states
  • Administration Notes: Frequently researched in conjunction with GHRH analogs and recovery-focused protocols

3. Typical Research Protocols

  • Product Strength: 3.33 mg/mL
  • Typical Delivered Amount: 100–300 mcg per dose
  • Frequency: 1–3 times daily
  • Cycle Length: 8–16 weeks on / 2–4 weeks off
  • Special Notes: GHRP-2 is commonly discussed as one of the more potent appetite-stimulating growth hormone secretagogues, and increased hunger can become significant at higher doses. Researchers frequently pair it with CJC-1295 or other GHRH analogs in an attempt to amplify pulsatile growth hormone signaling. Because GHRP-2 may increase cortisol and prolactin more noticeably than some newer secretagogues, conservative dosing and periodic cycling are commonly emphasized. Many users prefer administering doses in a fasted state to avoid insulin and blood-glucose interference with growth hormone release.

4. Summary

GHRP-2 is an experimental growth hormone releasing peptide researched for its potential effects on pulsatile growth hormone release, recovery, appetite signaling, and anabolic support pathways.

Research interest in GHRP-2 commonly centers around recovery enhancement, body composition support, growth hormone optimization, and performance-oriented applications.

5. Mechanism of Action

GHRP-2 functions by stimulating ghrelin receptors and influencing pulsatile growth hormone release pathways.

  • Growth hormone release signaling
  • Ghrelin receptor activation
  • Potential appetite stimulation
  • Recovery signaling support
  • Possible IGF-1 enhancement
  • Metabolic pathway modulation

The peptide is commonly researched as part of multi-compound growth hormone optimization protocols.

6. Potential Benefits

  • Potential increase in growth hormone signaling
  • Enhanced recovery support
  • Possible sleep-quality improvements
  • Potential body composition support
  • Increased appetite signaling
  • Possible synergistic effects with GHRH analogs

7. Potential Risks / Side Effects

Moderate/High

  • Increased hunger
  • Water retention
  • Elevated cortisol signaling
  • Elevated prolactin signaling
  • Numbness or tingling
  • Fatigue
  • Potential insulin sensitivity changes

8. Half-Life

GHRP-2 is commonly discussed as having a relatively short plasma half-life.

However, downstream growth hormone and IGF-1 signaling effects may persist considerably longer than measurable plasma concentrations.

9. Storage Information

  • Store refrigerated before and after reconstitution
  • Protect from direct light exposure
  • Avoid repeated freeze-thaw cycles
  • Maintain sterile handling practices during preparation

10. Contraindications / Warnings

  • Active cancer concerns
  • Uncontrolled diabetes
  • Pregnancy or breastfeeding
  • Known hypersensitivity to peptide compounds
  • Use alongside multiple hormone-modulating compounds without supervision

11. Research References

  • PubMed
  • NIH Publications
  • Endocrinology literature
  • Peer-reviewed growth hormone and metabolism journals